In:
Future Oncology, Future Medicine Ltd, Vol. 19, No. 25 ( 2023-08), p. 1729-1739
Abstract:
Objective: To investigate the safety and efficacy of anlotinib hydrochloride capsules in stage III–IV non-small-cell lung cancer (NSCLC). Methods: NSCLC patients received anlotinib monotherapy or combination therapy. The primary end point was adverse reactions during anlotinib treatment and the secondary end point was progression-free survival. Results: During anlotinib treatement, 41.85% (167/399) of patients experienced adverse reactions, and the monotherapy group had a lower incidence than the combination group (36.89 vs 49.68%; p = 0.012). The median progression-free survival of patients in the monotherapy group was significantly lower than that in the combination group (5 vs 6 months; p = 0.0119). Conclusion: Compared with anlotinib monotherapy, combination therapy resulted in longer PFS and a higher incidence of adverse reactions in patients with NSCLC.
Type of Medium:
Online Resource
ISSN:
1479-6694
,
1744-8301
DOI:
10.2217/fon-2023-0470
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2023
